448 related articles for article (PubMed ID: 33334586)
61. Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
Jin F; Gao D; Wu Q; Liu F; Chen Y; Tan C; Jiang Y
Bioorg Med Chem; 2013 Sep; 21(18):5694-706. PubMed ID: 23932071
[TBL] [Abstract][Full Text] [Related]
62. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
[TBL] [Abstract][Full Text] [Related]
63. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
[TBL] [Abstract][Full Text] [Related]
64. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Bioorg Med Chem; 2014 Sep; 22(17):4735-44. PubMed ID: 25082515
[TBL] [Abstract][Full Text] [Related]
65. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
66. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z
Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745
[TBL] [Abstract][Full Text] [Related]
67. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers.
Alanazi MM; Eissa IH; Alsaif NA; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Elkady H; Elwan A
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1760-1782. PubMed ID: 34340610
[TBL] [Abstract][Full Text] [Related]
68. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
[TBL] [Abstract][Full Text] [Related]
69. Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles.
Abdel-Mohsen HT; Abdullaziz MA; Kerdawy AME; Ragab FAF; Flanagan KJ; Mahmoud AEE; Ali MM; Diwani HIE; Senge MO
Molecules; 2020 Feb; 25(4):. PubMed ID: 32053964
[TBL] [Abstract][Full Text] [Related]
70. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
71. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
[TBL] [Abstract][Full Text] [Related]
72. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
[TBL] [Abstract][Full Text] [Related]
73. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
74. Novel NO-TZDs and trimethoxychalcone-based DHPMs: design, synthesis, and biological evaluation as potential VEGFR-2 inhibitors.
Mahnashi MH; Nahari M; Almasoudi H; Alhasaniah A; Elgazwi S; Abou-Salim MA
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2358934. PubMed ID: 38904116
[TBL] [Abstract][Full Text] [Related]
75. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
[TBL] [Abstract][Full Text] [Related]
76. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and
Hagras M; Saleh MA; Ezz Eldin RR; Abuelkhir AA; Khidr EG; El-Husseiny AA; El-Mahdy HA; Elkaeed EB; Eissa IH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):380-396. PubMed ID: 34923885
[TBL] [Abstract][Full Text] [Related]
77. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
[TBL] [Abstract][Full Text] [Related]
78. New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition.
El-Fakharany ZS; Nissan YM; Sedky NK; Arafa RK; Abou-Seri SM
Sci Rep; 2023 Jul; 13(1):11346. PubMed ID: 37443185
[TBL] [Abstract][Full Text] [Related]
79. New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation.
Abdallah AE; Mabrouk RR; Elnagar MR; Farrag AM; Kalaba MH; Sharaf MH; El-Fakharany EM; Bakhotmah DA; Elkaeed EB; Al Ward MMS
Drug Des Devel Ther; 2022; 16():587-606. PubMed ID: 35281317
[TBL] [Abstract][Full Text] [Related]
80. Synthesis and biological evaluation of diaryl urea derivatives designed as potential anticarcinoma agents using de novo structure-based lead optimization approach.
Azimian F; Hamzeh-Mivehroud M; Shahbazi Mojarrad J; Hemmati S; Dastmalchi S
Eur J Med Chem; 2020 Sep; 201():112461. PubMed ID: 32663641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]